TiumBio Co., Ltd. Logo

TiumBio Co., Ltd.

Clinical-stage biopharma developing therapies for rare diseases, gynecology, and hemophilia.

321550 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 창업로40번길 30 6층 (시흥동, 판교아이티센터), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TiumBio Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutics for rare and incurable diseases. The company leverages its expertise in both small-molecule synthetic drugs and biologics to build a robust pipeline targeting areas with high unmet medical needs and significant growth potential. Its lead clinical programs include Merigolix (TU2670), an oral GnRH antagonist for treating gynecological conditions like endometriosis and uterine fibroids, and TU7710, a long-acting recombinant protein for hemophilia. Founded in 2016, TiumBio is also expanding its R&D capabilities into next-generation therapies, including bispecific antibodies and antibody-drug conjugates (ADCs), to create market value through its distinct portfolio.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for TiumBio Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-07-22 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.6 KB
2025-07-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.8 KB

Automate Your Workflow. Get a real-time feed of all TiumBio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for TiumBio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888
StemRIM Inc. Logo
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan 4599
STENOCARE A/S Logo
Develops and distributes prescription medical cannabis oils in Northern Europe and Australia.
Denmark STENO
ST PHARM CO., LTD. Logo
A global CDMO specializing in APIs and RNA therapeutics for the gene therapy market.
South Korea 237690
Sugentech, Inc. Logo
Develops advanced in-vitro diagnostic systems for hospitals, clinics, and at-home use.
South Korea 253840
SUHEUNG CO.,LTD. Logo
Global manufacturer of capsules and contract manufacturing for pharma/nutraceutical industries.
South Korea 008490
Sumitomo Pharma Co., Ltd. Logo
R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.
Japan 4506
SunBio, Inc. Logo
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea 067370
Swedish Orphan Biovitrum Logo
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden SOBI
SymBio Pharmaceuticals Limited Logo
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan 4582

Talk to a Data Expert

Have a question? We'll get back to you promptly.